Payment overview · 2025
General Payments
$1,861.25
108 reported records · 22 companies
Healthcare provider profile · identity verified
Joseph L Putman, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, IN · NPI 1902807209
Verified facts
What the public records show
CMS Open Payments records show Joseph L Putman, MD received $1,861.25 in general payments during 2025 across 108 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Qulipta, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $351.77 | 18.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.16 | 17.9% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $259.41 | 13.9% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $200.21 | 10.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.20 | 8.1% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.69 | 4.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.53 | 4.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.93 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.22 | 2.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.88 | 2.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.02 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.69 | 1.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.98 | 1.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.17 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.55 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.83 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.60 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.82 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.06 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.48 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.35 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.70 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,861.25 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $310.40 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $206.24 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $200.21 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.19 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $166.81 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $161.85 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.69 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $115.67 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.08 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $79.96 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $78.69 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.50 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.01 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.46 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.46 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.77 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.18 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.70 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $11.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 178 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
178 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 184 |
| Lisinopril | Lisinopril | 467 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 106 |
| Metformin Hcl | Metformin Hcl | 310 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 71 |
| Omeprazole | Omeprazole | 232 | 69 |
| Furosemide | Furosemide | 227 | 65 |
| Valsartan | Valsartan | 217 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 178 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 64 |
| Carvedilol | Carvedilol | 171 | 45 |
| Gabapentin | Gabapentin | 167 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 47 |
| Allopurinol | Allopurinol | 153 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 29 |
| Metformin Hcl Er | Metformin Hcl | 124 | 35 |
| Glipizide Er | Glipizide | 123 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 32 |
| Mounjaro | Tirzepatide | 117 | 20 |
| Losartan Potassium | Losartan Potassium | 109 | 28 |
| Farxiga | Dapagliflozin Propanediol | 107 | 23 |
| Alendronate Sodium | Alendronate Sodium | 104 | 30 |
| Trazodone Hcl | Trazodone Hcl | 103 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 25 |
| Ozempic | Semaglutide | 97 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 25 |
| Potassium Chloride | Potassium Chloride | 89 | 27 |
| Simvastatin | Simvastatin | 80 | 23 |
| Spironolactone | Spironolactone | 80 | 25 |
| Lovastatin | Lovastatin | 74 | 18 |
| Januvia | Sitagliptin Phosphate | 73 | 19 |
| Jardiance | Empagliflozin | 69 | 20 |
| Buspirone Hcl | Buspirone Hcl | 67 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 19 |
| Memantine Hcl Er | Memantine Hcl | 58 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 14 |
| Sertraline Hcl | Sertraline Hcl | 58 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 14 |
| Primidone | Primidone | 54 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Bupropion Xl | Bupropion Hcl | 51 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Klor-Con M20 | Potassium Chloride | 49 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Famotidine | Famotidine | 42 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Irbesartan | Irbesartan | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 36 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 23 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 12 |
| Prednisone | Prednisone | 34 | 24 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Meloxicam | Meloxicam | 32 | 13 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Finasteride | Finasteride | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 24 |
| Eliquis | Apixaban | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Cephalexin | Cephalexin | 15 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Prolia | Denosumab | 14 | 12 |
| Qulipta | Atogepant | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,861.25 · 108 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error